BidaskClub upgraded shares of Cutera (NASDAQ:CUTR) from a hold rating to a buy rating in a research report sent to investors on Tuesday.

CUTR has been the topic of several other reports. Maxim Group downgraded Cutera from a buy rating to a hold rating in a research note on Thursday, September 14th. Zacks Investment Research downgraded Cutera from a buy rating to a hold rating in a research note on Tuesday, October 10th. TheStreet upgraded Cutera from a c rating to a b rating in a research note on Friday, August 18th. Finally, Roth Capital boosted their target price on Cutera from $41.00 to $47.00 and gave the stock a buy rating in a research note on Tuesday, September 12th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Cutera has a consensus rating of Buy and an average price target of $37.33.

Shares of Cutera (CUTR) traded down $1.30 during mid-day trading on Tuesday, reaching $47.20. The company had a trading volume of 2,466,300 shares, compared to its average volume of 160,873. Cutera has a 1 year low of $16.55 and a 1 year high of $48.95. The stock has a market cap of $661.04, a P/E ratio of 62.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.53.

Cutera (NASDAQ:CUTR) last announced its earnings results on Tuesday, November 7th. The medical device company reported $0.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.34. Cutera had a return on equity of 18.73% and a net margin of 7.99%. The firm had revenue of $38.17 million for the quarter, compared to the consensus estimate of $34.82 million. During the same period in the previous year, the business earned $0.12 EPS. The firm’s revenue for the quarter was up 26.1% on a year-over-year basis. research analysts predict that Cutera will post 0.55 EPS for the current fiscal year.

In other news, Director David B. Apfelberg sold 1,000 shares of the business’s stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $39.90, for a total value of $39,900.00. Following the completion of the transaction, the director now owns 10,259 shares of the company’s stock, valued at approximately $409,334.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Timothy J. Oshea sold 4,000 shares of the business’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $39.21, for a total value of $156,840.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,950 shares of company stock worth $1,076,770. Company insiders own 11.60% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Morgan Stanley raised its holdings in Cutera by 23.3% in the 1st quarter. Morgan Stanley now owns 67,345 shares of the medical device company’s stock worth $1,395,000 after purchasing an additional 12,734 shares during the period. Teachers Advisors LLC raised its holdings in Cutera by 50.7% in the 2nd quarter. Teachers Advisors LLC now owns 62,702 shares of the medical device company’s stock worth $1,624,000 after purchasing an additional 21,088 shares during the period. Kennedy Capital Management Inc. acquired a new position in Cutera in the 2nd quarter worth about $9,426,000. Scout Investments Inc. acquired a new position in Cutera in the 2nd quarter worth about $1,454,000. Finally, Renaissance Technologies LLC raised its holdings in Cutera by 0.8% in the 2nd quarter. Renaissance Technologies LLC now owns 1,214,500 shares of the medical device company’s stock worth $31,456,000 after purchasing an additional 9,100 shares during the period. 87.64% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Cutera (CUTR) Lifted to “Buy” at BidaskClub” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/15/cutera-cutr-lifted-to-buy-at-bidaskclub.html.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Receive News & Stock Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related stocks with our FREE daily email newsletter.